Tremelimumab

Drug Profile

Tremelimumab

Alternative Names: CP-675; CP-675,206; Ticilimumab

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Amgen; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Immunocore; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Phase I/II Malignant melanoma; Peritoneal cancer
  • Phase I Colorectal cancer; Diffuse large B cell lymphoma; Renal cell carcinoma; Urogenital cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 23 Mar 2017 AstraZeneca plans a phase III trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease) in USA and Canada (NCT03084471)
  • 14 Mar 2017 Dana-Farber Cancer Institute and AstraZeneca plan a phase II trial for Mesothelioma (Combination therapy) in USA (NCT03057106)
  • 03 Mar 2017 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, First-line therapy, Combination therapy) in China (IV) before March 2017 (NCT02542293)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top